Recent results from a systematic review led by an international research consortium indicate that paracetamol does not increase the risk of autism spectrum disorders in children born to mothers who used the medication during pregnancy. The analysis included data from 25 prospective cohort studies comprising over 200,000 mother–child pairs and applied rigorous statistical methods to assess dose–response relationships. The investigators found that any observed associations in earlier, smaller studies were attenuated after adjusting for confounders such as maternal age, socioeconomic status, and health status. The findings suggest that the analgesic remains an appropriate option for pain relief in pregnancy when used at standard therapeutic doses. _2_ The study’s results directly address concerns that were raised by a high‑profile political figure who had previously claimed a connection between paracetamol use during pregnancy and autism. By demonstrating a lack of evidence for a causal link, the review adds to a growing body of literature that supports continued clinical use of the drug. The authors also highlighted the need for clinicians to balance benefits and risks, especially in cases of severe pain or fever. _3_ The scientific community has generally emphasized that non‑opioid analgesics like paracetamol are preferable in the prenatal setting due to their lower risk profile compared to alternatives such as NSAIDs. The new review reinforces existing guidelines issued by obstetric and pediatric societies, encouraging evidence‑based prescribing practices while maintaining public confidence in safe medication use during pregnancy.